Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

Authors

Tony Mok
Kazuhiko Nakagawa
Keunchil Park
Yuichiro Ohe
Nicolas Girard
Hye Ryun Kim
Yi-Long Wu
Justin Gainor
Se-Hoon Lee
Chao-Hua Chiu
Sang-We Kim
Cheng-Ta Yang
Chien Liang Wu
Lin Wu
Meng-Chih Lin
Jens Samol
Kazuya Ichikado
Mengzhao Wang
Xiaoqing Zhang
Judi Sylvester
Sunney Li
Ann Forslund
James Chih-Hsin Yang

Publication Date

4-10-2024

Abstract

PURPOSE: The phase III CheckMate 722 trial (ClinicalTrials.gov identifier: NCT02864251) evaluated nivolumab plus chemotherapy versus chemotherapy in patients with epidermal growth factor receptor (

METHODS: Patients with disease progression after first- or second-generation EGFR TKI therapy (without

RESULTS: Overall, 294 patients were randomly assigned. At final analysis (median follow-up, 38.1 months), PFS was not significantly improved with nivolumab plus chemotherapy versus chemotherapy (median, 5.6

CONCLUSION: Nivolumab plus chemotherapy did not significantly improve PFS versus chemotherapy in patients with

Keywords

Humans, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Disease Progression, ErbB Receptors, Lung Neoplasms, Mutation, Nivolumab, Platinum, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors

DOI

10.1200/JCO.23.01017

PMID

38252907

PMCID

PMC11095864

PubMedCentral® Posted Date

1-22-2024

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes